Genomtec S.A. Logo

Genomtec S.A.

Develops mobile platforms for rapid, point-of-care molecular diagnostics.

GMT | WAR

Overview

Corporate Details

ISIN(s):
PLGNMTC00017
LEI:
259400ND13Y44ADMG554
Country:
Poland
Address:
WROCŁAW BIERUTOWSKA 57-59, 51-317 WROCŁAW

Description

Genomtec S.A. is a technology company specializing in the development of mobile platforms for rapid molecular diagnostics. The company's flagship product is Genomtec ID, a portable point-of-care system for genetic testing that combines the amplification and detection of specific DNA and RNA fragments. This technology enables fast and accurate analysis without requiring specialized laboratory infrastructure or personnel. A key application is the CE-IVD certified GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which detects viruses and bacteria causing respiratory tract infections. The company has also organized its core technologies, the Genomtec ID platform and the OncoSNAAT oncology project, into separate special purpose vehicles to facilitate strategic development and potential M&A processes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-23 17:26
Aktualizacja informacji w sprawie strategicznych kierunków współpracy - Content…
Polish 1.1 KB
2025-12-11 14:27
Otrzymanie od Urzędu Patentowego w Stanach Zjednoczonych decyzji o udzieleniu o…
Polish 2.0 KB
2025-11-28 17:32
zal01_Genomtec_sprawozdanie_III_kw_2025.pdf
Polish 940.2 KB
2025-11-28 17:32
zal02_GENOMTEC_Pozostale_informacje_do_3Q2025.pdf
Polish 958.9 KB
2025-10-15 16:44
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.4 KB
2025-09-29 18:10
zal04_opinia_RN_do_stanowiska.pdf
Polish 154.5 KB
2025-09-29 18:10
zal05_Stanowisko_Zarzadu_do_zastrzezenia.pdf
Polish 144.6 KB
2025-09-29 18:10
zal03_genomtec_sprawozdanie_zarzadu_ip_2025_vfinal_signed_1.pdf
Polish 1.1 MB
2025-09-29 18:10
zal02_GENOMTEC_PSF_2025_MSR_Raport_z_przegladu_ost.pdf
Polish 420.3 KB
2025-09-29 18:10
zal01_genomtec_sf_06.2025_sig_signed.pdf
Polish 1.6 MB
2025-09-25 17:13
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.6 KB
2025-09-15 17:12
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 2.0 KB
2025-09-15 17:08
Podjęcie przez Zarząd Giełdy Papierów Wartościowych uchwały w sprawie dopuszcze…
Polish 1.0 KB
2025-09-11 17:57
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowegoPrzyznan…
Polish 2.3 KB
2025-08-14 17:28
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowego - Conte…
Polish 2.2 KB

Automate Your Workflow. Get a real-time feed of all Genomtec S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genomtec S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genomtec S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.